- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.04. | Femasys reports FY results | 1 | Seeking Alpha | ||
| 28.03. | H.C. Wainwright maintains Femasys stock Buy rating, $15 target | 1 | Investing.com | ||
| 27.03. | FEMASYS INC - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 27.03. | FEMASYS INC - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | FEMASYS INC - 8-K, Current Report | 3 | SEC Filings | ||
| FEMASYS Aktie jetzt für 0€ handeln | |||||
| 27.03. | Femasys Inc.: Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update | 96 | GlobeNewswire (Europe) | -- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025... ► Artikel lesen | |
| 20.03. | H.C. Wainwright raises Femasys stock price target to $15 | - | Investing.com | ||
| 19.03. | Femasys Inc.: Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations | 2 | GlobeNewswire (USA) | ||
| 18.03. | Assessing Femasys: Insights From 4 Financial Analysts | 2 | Benzinga.com | ||
| 14.03. | H.C. Wainwright maintains Femasys stock Buy rating, $12 target | 1 | Investing.com | ||
| 13.03. | Femasys erhält CE-Kennzeichnung für nicht-chirurgisches Verhütungssystem | 1 | Investing.com Deutsch | ||
| 13.03. | FEMASYS INC - 8-K, Current Report | 3 | SEC Filings | ||
| 13.03. | Femasys Inc.: Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach | 104 | GlobeNewswire (Europe) | ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive... ► Artikel lesen | |
| 25.02. | Femasys Inc.: Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc Permanent Birth Control Clinical Trials | 171 | GlobeNewswire (Europe) | --Positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners-- ATLANTA, Feb. 25, 2025 (GLOBE... ► Artikel lesen | |
| 11.02. | Femasys gains UK approval for women's health products | 2 | Investing.com | ||
| 11.02. | Femasys erhält britische Zulassung für Produkte im Bereich Frauengesundheit | 7 | Investing.com Deutsch | ||
| 11.02. | Femasys Inc.: Femasys Announces UK Regulatory Approvals for FemaSeed for Female Infertility Treatment and Two Diagnostic Devices | 1 | GlobeNewswire (USA) | ||
| 04.02. | Femasys Inc.: Femasys Announces Israeli Regulatory Approvals for FemaSeed for Female Infertility Treatment and Two Diagnostic Devices | 148 | GlobeNewswire (Europe) | ATLANTA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive... ► Artikel lesen | |
| 30.01. | Femasys announces notices of intention to grant for two new European patent applications | 5 | Seeking Alpha | ||
| 30.01. | Femasys Inc.: Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control | 188 | GlobeNewswire (Europe) | ATLANTA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive... ► Artikel lesen |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 425,65 | +0,32 % | Aktienmarkt: Aktie von Intuitive Surgical tritt auf der Stelle (431,2205 €) | Im US-amerikanischen Wertpapierhandel ist das Wertpapier von Intuitive Surgical derzeit unauffällig. Der jüngste Kurs betrug 489,28 US-Dollar. Wenig getan hat sich heute bislang beim Kurs von Intuitive... ► Artikel lesen | |
| ROKU | 51,24 | -0,29 % | Roku to Collaborate with Adobe on Real-Time Customer Data | ||
| ATOSSA THERAPEUTICS | 0,540 | -1,46 % | Nona Biosciences and Atossa team up to discover breast cancer therapies | ||
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| TEMPEST THERAPEUTICS | 7,050 | 0,00 % | Tempest Therapeutics: Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value | Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global investigator support in placeAwarded both Orphan Drug... ► Artikel lesen | |
| QUIDELORTHO | 21,800 | -1,80 % | QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results | SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care... ► Artikel lesen | |
| VERU | 0,470 | -0,21 % | Veru Aktie: Auf der Stelle treten! | Biopharma-Wertpapier verliert knapp 4% und setzt Negativtrend fort, während Experten überraschend ein Kurspotenzial von bis zu 500% prognostizieren. Die Veru-Aktie setzt ihren anhaltenden Abwärtstrend... ► Artikel lesen | |
| CENTENE | 53,66 | +0,52 % | Centene-Aktie: Kurs heute nahezu konstant (54,8912 €) | Wenig Kursbewegung gegenwärtig bei der Centene-Aktie . Die Aktie kostete zuletzt 62,47 US-Dollar. Eine geringe Verteuerung von 0,31 Prozent zeigt die Kurstafel für das Wertpapier von Centene an. Die... ► Artikel lesen | |
| NANO-X IMAGING | 5,180 | -0,38 % | Nano-X Imaging LTD.: Nanox Receives FDA Clearance for General Use of New Imaging System, Nanox.ARC X | First FDA clearance for Nanox.ARC X to produce tomographic images for general use, including musculoskeletal, pulmonary, intra-abdominal and paranasal indicationsEnhanced imaging system features sleek... ► Artikel lesen | |
| FULGENT GENETICS | 16,600 | +5,06 % | Fulgent Reports Third Quarter 2024 Financial Results | EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic... ► Artikel lesen | |
| LANTHEUS | 87,02 | -2,36 % | Lantheus Holdings, Inc.: Lantheus Completes Acquisition of Evergreen Theragnostics | BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 1,650 | -2,94 % | Perspective Therapeutics, Inc.: Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results | ||
| AMN HEALTHCARE SERVICES | 15,400 | +1,99 % | AMN Healthcare Services Inc. Q4 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for AMN Healthcare Services Inc. (AMN):Earnings: -$187.53 million in Q4 vs. $12.49 million in the same period last year.
EPS: -$4.90... ► Artikel lesen | |
| OMNICELL | 27,200 | +1,49 % | Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results | FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery... ► Artikel lesen | |
| ALPHATEC | 9,018 | 0,00 % | Alphatec stock holds Buy rating and $20 target at H.C. Wainwright |
FEMASYS INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,240 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FEMASYS INC finden Sie auf Wallstreet Online.
